Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

PURPOSE: The median overall survival (OS) for metastatic pancreatic ductal adenocarcinoma (mPDAC) is < 1 year. Factors that contribute to quality of life during treatment are critical to quantify. One factor—time spent obtaining clinical services—is understudied. We quantified total outpatient ti...

全面介紹

Na minha lista:
書目詳細資料
發表在:JCO Oncol Pract
Main Authors: Bange, Erin M., Doucette, Abigail, Gabriel, Peter E., Porterfield, Florence, Harrigan, James J., Wang, Robin, Wojcieszynski, Andrzej P., Boursi, Ben, Mooney, Bethany I., Reiss, Kim A., Mamtani, Ronac
格式: Artigo
語言:Inglês
出版: American Society of Clinical Oncology 2020
主題:
ORIGINAL CONTRIBUTIONS
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7427417/
https://ncbi.nlm.nih.gov/pubmed/32130074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JOP.19.00328
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍